ADMA (ADMA Biologics) Moat Score : 4/10 (As of Jul. 08, 2025)

View and export this data going back to 2013. Start your Free Trial

What is ADMA Biologics Moat Score?

ADMA Biologics has the Moat Score of 4, which implies that the company might have Narrow Moat - Discernible but modest moat.

ADMA Biologics has Narrow Moat: ADMA Biologics has valuable intellectual property and patents in the biologics space, providing some competitive edge. However, it lacks strong market leadership and brand strength. The company has moderate regulatory barriers but limited cost advantages and customer loyalty.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes ADMA Biologics might have Narrow Moat - Discernible but modest moat.

Competitive Comparison of ADMA Biologics's Moat Score

For the Biotechnology subindustry, ADMA Biologics's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ADMA Biologics's Moat Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ADMA Biologics's Moat Score distribution charts can be found below:

* The bar in red indicates where ADMA Biologics's Moat Score falls into.

Save Embed

;

Save Embed

;

ADMA Biologics (NAS:ADMA) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score	Moat Level
10	Wide Moat - Exceptionally dominant and durable wide moat
8 - 9	Wide Moat - Clear and robust wide moat
7	Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6	Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5	Narrow Moat - Solid narrow moat
4	Narrow Moat - Discernible but modest moat
1 - 3	No Moat - Very weak/transient advantages
0	No Moat - No discernible moat

ADMA Biologics Moat Score Related Terms

Thank you for viewing the detailed overview of ADMA Biologics's Moat Score provided by GuruFocus.com. Please click on the following links to see related term pages.

ADMA Biologics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ADMA Biologics Inc (NAS:ADMA) » Definitions » Moat Score

Comparable Companies

Traded in Other Exchanges

N/A

Address

465 State Route 17, Ramsey, NJ, USA, 07446

Website

https://www.admabiologics.com

ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.

Executives

Lawrence P. Guiheen	director	65 COMMERCE WAY, HACKENSACK NJ 07601
Adam S Grossman	director, officer: President and CEO	65 COMMERCE WAY, HACKENSACK NJ 07601
Jerrold B Grossman	director	65 COMMERCE WAY, HACKENSACK NJ 07601
Young Kwon	director	C/O MOMENTA PHARMACEUTICALS INC., 675 WEST KENDALL STREET, CAMBRIDGE MA 02142
Steve Elms	director	888 SEVENTH AVE, 29TH FL, NEW YORK NY 10106
Alison Cecily Finger	director	C/O BLUEBIRD BIO, INC., 60 BINNEY STREET, CAMBRIDGE MA 02142
Bryant Fong	director	2170 VALLEJO STREET #101, SAN FRANCISCO CA 94123
Brian Lenz	officer: EVP, CFO	65 COMMERCE WAY, HACKENSACK NJ 07601
Martha J Demski	director	7770 REGENTS ROAD SUITE 113-505, SAN DIEGO CA 92122
Perceptive Life Sciences Master Fund Ltd	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
James Mond	officer: CSO/CMO	65 COMMERCE WAY, HACKENSACK NJ 07601
Biotest Divestiture Trust	10 percent owner	C/O ERIC ROSENBACH, TRUSTEE, 402 NORFOLK STREET, CAMBRIDGE MA 02139
Perceptive Advisors Llc	10 percent owner	51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Joseph Edelman	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Eric I Richman	director	C/O REV CAPITAL II, LLC, 9740 SORREL AVE, POTOMAC MD 20854